Terms: = Bone cancer AND RAF1, Raf-1, 5894, P04049, ENSG00000132155, c-Raf, CRAF AND Treatment
24 results:
1. Decabromodiphenyl ether exposure reduces dabrafenib sensitivity of papillary thyroid carcinoma harboring BRAF
Wang X; Cui X; Wang Y; Wang Q; Sun F; Liu Z
Toxicology; 2024 May; 504():153807. PubMed ID: 38641160
[TBL] [Abstract] [Full Text] [Related]
2. Procoxacin bidirectionally inhibits osteoblastic and osteoclastic activity in bone and suppresses bone metastasis of prostate cancer.
Kong D; Ye C; Zhang C; Sun X; Wang F; Chen R; Xiao G; He S; Xu J; Rao X; Ai J; Gao X; Li H; Su L
J Exp Clin Cancer Res; 2023 Feb; 42(1):45. PubMed ID: 36759880
[TBL] [Abstract] [Full Text] [Related]
3. Optimisation of pyrazolo[1,5-a]pyrimidin-7(4H)-one derivatives as novel Hsp90 C-terminal domain inhibitors against Ewing sarcoma.
Zajec Ž; Dernovšek J; Distel M; Gobec M; Tomašič T
Bioorg Chem; 2023 Feb; 131():106311. PubMed ID: 36495678
[TBL] [Abstract] [Full Text] [Related]
4. BRAF mutation and its inhibitors in sarcoma treatment.
Liu H; Nazmun N; Hassan S; Liu X; Yang J
Cancer Med; 2020 Jul; 9(14):4881-4896. PubMed ID: 32476297
[TBL] [Abstract] [Full Text] [Related]
5. Tomatidine Alleviates Osteoporosis by Downregulation of p53.
Yu T; Wu Q; You X; Zhou H; Xu S; He W; Li Z; Li B; Xia J; Zhu H; Zhao Y; Yang Y; Chen K
Med Sci Monit; 2020 Apr; 26():e923996. PubMed ID: 32300098
[TBL] [Abstract] [Full Text] [Related]
6. Tomatidine Represses Invasion and Migration of Human Osteosarcoma U2OS and HOS Cells by Suppression of Presenilin 1 and c-raf-MEK-ERK Pathway.
Hsieh MH; Yang JS; Lin RC; Hsieh YH; Yang SF; Chang HR; Lu KH
Molecules; 2020 Jan; 25(2):. PubMed ID: 31941156
[TBL] [Abstract] [Full Text] [Related]
7. A Multifunctional Therapy Approach for cancer: Targeting raf1- Mediated Inhibition of Cell Motility, Growth, and Interaction with the Microenvironment.
Zhang L; Pattanayak A; Li W; Ko HK; Fowler G; Gordon R; Bergan R
Mol Cancer Ther; 2020 Jan; 19(1):39-51. PubMed ID: 31582531
[TBL] [Abstract] [Full Text] [Related]
8. Commentary on "Integrative clinical genomics of advanced prostate cancer". Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.Cell. 21 May 2015;161(5):1215-1228.
Freedland SJ; Aronson WJ
Urol Oncol; 2017 Aug; 35(8):535. PubMed ID: 28623072
[TBL] [Abstract] [Full Text] [Related]
9. Zoledronic acid is an effective radiosensitizer in the treatment of osteosarcoma.
Kim EH; Kim MS; Lee KH; Koh JS; Jung WG; Kong CB
Oncotarget; 2016 Oct; 7(43):70869-70880. PubMed ID: 27765919
[TBL] [Abstract] [Full Text] [Related]
10. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
Rutkowski P; Stępniak J
Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
[TBL] [Abstract] [Full Text] [Related]
11. Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells.
Suzuki R; Kikuchi S; Harada T; Mimura N; Minami J; Ohguchi H; Yoshida Y; Sagawa M; Gorgun G; Cirstea D; Cottini F; Jakubikova J; Tai YT; Chauhan D; Richardson PG; Munshi N; Ando K; Utsugi T; Hideshima T; Anderson KC
PLoS One; 2015; 10(12):e0143847. PubMed ID: 26630652
[TBL] [Abstract] [Full Text] [Related]
12. Organ-specific efficacy of HSP90 inhibitor in multiple-organ metastasis model of chemorefractory small cell lung cancer.
Takeuchi S; Fukuda K; Arai S; Nanjo S; Kita K; Yamada T; Hara E; Nishihara H; Uehara H; Yano S
Int J Cancer; 2016 Mar; 138(5):1281-9. PubMed ID: 26379118
[TBL] [Abstract] [Full Text] [Related]
13. Integrative clinical genomics of advanced prostate cancer.
Robinson D; Van Allen EM; Wu YM; Schultz N; Lonigro RJ; Mosquera JM; Montgomery B; Taplin ME; Pritchard CC; Attard G; Beltran H; Abida W; Bradley RK; Vinson J; Cao X; Vats P; Kunju LP; Hussain M; Feng FY; Tomlins SA; Cooney KA; Smith DC; Brennan C; Siddiqui J; Mehra R; Chen Y; Rathkopf DE; Morris MJ; Solomon SB; Durack JC; Reuter VE; Gopalan A; Gao J; Loda M; Lis RT; Bowden M; Balk SP; Gaviola G; Sougnez C; Gupta M; Yu EY; Mostaghel EA; Cheng HH; Mulcahy H; True LD; Plymate SR; Dvinge H; Ferraldeschi R; Flohr P; Miranda S; Zafeiriou Z; Tunariu N; Mateo J; Perez-Lopez R; Demichelis F; Robinson BD; Schiffman M; Nanus DM; Tagawa ST; Sigaras A; Eng KW; Elemento O; Sboner A; Heath EI; Scher HI; Pienta KJ; Kantoff P; de Bono JS; Rubin MA; Nelson PS; Garraway LA; Sawyers CL; Chinnaiyan AM
Cell; 2015 May; 161(5):1215-1228. PubMed ID: 26000489
[TBL] [Abstract] [Full Text] [Related]
14. Overexpression of raf-1 and ERK1/2 in sacral chordoma and association with tumor recurrence.
Zhang K; Chen H; Zhang B; Sun J; Lu J; Chen K; Yang H
Int J Clin Exp Pathol; 2015; 8(1):608-14. PubMed ID: 25755752
[TBL] [Abstract] [Full Text] [Related]
15. Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations.
Traer E; Javidi-Sharifi N; Agarwal A; Dunlap J; English I; Martinez J; Tyner JW; Wong M; Druker BJ
Blood; 2014 Mar; 123(10):1516-24. PubMed ID: 24408322
[TBL] [Abstract] [Full Text] [Related]
16. Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.
Ambati SR; Lopes EC; Kosugi K; Mony U; Zehir A; Shah SK; Taldone T; Moreira AL; Meyers PA; Chiosis G; Moore MA
Mol Oncol; 2014 Mar; 8(2):323-36. PubMed ID: 24388362
[TBL] [Abstract] [Full Text] [Related]
17. Ras activation mediates WISP-1-induced increases in cell motility and matrix metalloproteinase expression in human osteosarcoma.
Wu CL; Tsai HC; Chen ZW; Wu CM; Li TM; Fong YC; Tang CH
Cell Signal; 2013 Dec; 25(12):2812-22. PubMed ID: 24036215
[TBL] [Abstract] [Full Text] [Related]
18. Epithelial-to-mesenchymal transition induced by TGF-β1 is mediated by Blimp-1-dependent repression of BMP-5.
Romagnoli M; Belguise K; Yu Z; Wang X; Landesman-Bollag E; Seldin DC; Chalbos D; Barillé-Nion S; Jézéquel P; Seldin ML; Sonenshein GE
Cancer Res; 2012 Dec; 72(23):6268-78. PubMed ID: 23054396
[TBL] [Abstract] [Full Text] [Related]
19. CCL2 increases MMP-9 expression and cell motility in human chondrosarcoma cells via the Ras/Raf/MEK/ERK/NF-κB signaling pathway.
Tang CH; Tsai CC
Biochem Pharmacol; 2012 Feb; 83(3):335-44. PubMed ID: 22138288
[TBL] [Abstract] [Full Text] [Related]
20. Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90.
Zhao M; Ma J; Zhu HY; Zhang XH; Du ZY; Xu YJ; Yu XD
Mol Cancer; 2011 Aug; 10():104. PubMed ID: 21871133
[TBL] [Abstract] [Full Text] [Related]
[Next]
